Mestag harnesses new insights into fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases. We are progressing a unique pipeline of novel antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology.
Mestag Therapeutics
Mestag Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £30m
- mestagtherapeutics.com
- Update Information
More venture news
- 17 Mar 2026
Sequential BioSequential secures £2.6m in funding led by Sparkfood and Corundum Systems Biology for non-invasive testing of skin health ingredients
EquityLife Sciences - 16 Mar 2026
Mestag TherapeuticsMestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
EquityLife Sciences - 16 Mar 2026
Ternary TherapeuticsTernary Therapeutics raises a £3.6m seed round led by daphni to engineer molecular glue medicines
SeedLife Sciences
